DK
Therapeutic Areas
Silence Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zerlasiran (SLN360) | Elevated Lipoprotein(a) for Cardiovascular Risk Reduction | Phase 2 |
| SLN124 | Iron-Refractory Iron Deficiency Anemia (IRIDA) | Phase 2 |
Leadership Team at Silence Therapeutics
CT
Craig Tooman
President and Chief Executive Officer
DD
Dr. David Horn Solomon
Chief Financial Officer
DR
Dr. Ralf Rosskamp
Chief Scientific Officer
DM
Dr. Michael G. Attenborough
Chief Business Officer
DI
Dr. Iain Ross
Chairman of the Board